Johnson & Johnson (NYSE:JNJ) Hits New 1-Year High – Here’s Why

Johnson & Johnson (NYSE:JNJ)’s stock price reached a new 52-week high during trading on Monday. The company traded as high as $282.33 and last traded at $282.5090, with a volume of 2,259,662 shares traded. The stock had previously closed at $276.22.

Johnson & Johnson News Roundup

Here’s some of the latest news about JNJ:

• Positive Sentiment: J&J reported a second successful Phase 3 study of CAPLYTA for bipolar I mania. The treatment improved symptoms versus placebo as early as Day 3, and the company plans to use results from two positive trials to support a U.S. FDA submission—potentially expanding the drug’s market opportunity. Reuters article
• Positive Sentiment: Oncology sales rose 16.8% to $22 billion in the first nine months of 2026, supported by established medicines and newer launches. That growth may help offset patent-related pressures. Oncology sales article
• Positive Sentiment: Coverage also points to a potential path to double-digit growth by 2030, as recent launches and changes to the business could support sales over the medium term. This is an outlook, not a guaranteed result. Growth outlook article

Analysts Set New Price Targets

Several analysts recently commented on the company. Evercore set a $300.00 price objective on Johnson & Johnson in a report on Tuesday, October 20th. Leerink Partners cut their price target on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. HSBC increased their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Royal Bank Of Canada dropped their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Trading Down 0.1%

The stock has a fifty day moving average of $266.49 and a 200 day moving average of $248.93. The company has a market capitalization of $675.29 billion, a P/E ratio of 42.54, a PEG ratio of 2.79 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Insider Buying and Selling

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP grew its position in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG lifted its holdings in Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock worth $3,927,981,000 after purchasing an additional 1,530,070 shares in the last quarter. Amundi lifted its holdings in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $1,967,399,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.